GTS Securities’s CureVac CVAC Stock Holding History

GTS Securities’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,218	Closed	-$104K	–	1890
2024 Q3	$104K	Buy	+35,218	New	+$116K	﹤0.01%	3794

Other funds holding CVAC

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

GTS Securities's CVAC Position: Q4 2024 in Review

GTS Securities sold out of CureVac (CVAC) in Q4 2024, closing a stake of 35,218 shares — an estimated $104K sold.

GTS Securities first reported a position in CVAC in Q3 2024 and held it in 1 quarter. The position peaked at $104K in Q3 2024. 75 funds tracked by Wall St. Rank hold CVAC as of Q4 2024.

GTS Securities reported no remaining CureVac position as of Q4 2024 after selling out during the quarter.
GTS Securities sold 35,218 CureVac shares in Q4 2024, an estimated $104K.
GTS Securities first reported a position in CureVac in Q3 2024 and held it in 1 quarter.
GTS Securities's CureVac position peaked at $104K in Q3 2024.
75 funds tracked by Wall St. Rank held CureVac as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.